Nuclear imaging of neuroendocrine tumours

Tiensuu Jansson, 2002, Malignant neuroendocrine tumors, Cancer Chemotherapy and Biological Response Modifiers, 20, 464 Rindi, 1998, Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors, Journal of Molecular Medicine, 76, 413, 10.1007/s001090050233 Patel, 1982, Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding on islets, Science, 217, 1155, 10.1126/science.6126003 Patel, 1997, Molecular pharmacology of somatostatin receptor subtypes, Journal of Endocrinological Investigation, 20, 348, 10.1007/BF03350317 Reubi, 2001, Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands, European Journal of Nuclear Medicine, 28, 836, 10.1007/s002590100541 Krenning, 1992, Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide, Journal of Nuclear Medicine, 5, 652 Krenning, 1989, Localization of endocrine-related tumors with radio iodinated analogue of somatostatin, Lancet, 1, 242, 10.1016/S0140-6736(89)91258-0 Krenning, 1993, Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-Octreotide: the Rotterdam experience with more than 1,000 patients, European Journal of Nuclear Medicine, 20, 716, 10.1007/BF00181765 Gibril, 1996, Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas, Annals of Internal Medicine, 125, 26, 10.7326/0003-4819-125-1-199607010-00005 Lebtahi, 1997, Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors, Journal of Nuclear Medicine, 6, 853 Termanini, 1997, Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management, Gastroenterology, 112, 335, 10.1053/gast.1997.v112.pm9024287 Kwekkeboom, 1999, Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake, Journal of Nuclear Medicine, 40, 762 Wild, 2005, 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5, European Journal of Nuclear Medicine and Molecular Imaging, 32, 724, 10.1007/s00259-004-1697-4 Ginj, 2005, Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy, Clinical Cancer Research, 11, 1136 Hubalewska-Dydejczyk, 2006, (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience, European Journal of Nuclear Medicine and Molecular Imaging, 33, 1123, 10.1007/s00259-006-0113-7 Storch, 2005, Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?, Journal of Nuclear Medicine, 46, 1561 Gabriel, 2003, An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors, Journal of Nuclear Medicine, 44, 708 Gabriel, 2004, 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy, Cancer Biotherapy & Radiopharmaceuticals, 19, 73, 10.1089/108497804773391702 Decristoforo, 2003, 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1211, 10.1007/s00259-003-1225-y Lebtahi, 2002, Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy, Journal of Nuclear Medicine, 43, 889 Kwekkeboom, 2005, Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors, Journal of Clinical Oncology, 23, 2754, 10.1200/JCO.2005.08.066 Esser, 2006, Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT?, European Journal of Nuclear Medicine and Molecular Imaging, 33, 1346, 10.1007/s00259-006-0172-9 Kwekkeboom, 2000, Peptide receptor imaging and therapy, Journal of Nuclear Medicine, 41, 1704 Bombardieri, 2003, 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging, European Journal of Nuclear Medicine and Molecular Imaging, 30, BP140 Schillaci, 1996, SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors, Journal of Nuclear Medicine, 37, 1452 Schillaci, 2003, Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors, Journal of Nuclear Medicine, 44, 359 Öberg, 2004, Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system, Annals of Oncology, 15, 966, 10.1093/annonc/mdh216 Dromain, 2005, Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging, Journal of Clinical Oncology, 23, 70, 10.1200/JCO.2005.01.013 Granberg, 2003, Octreoscan in patients with bronchial carcinoid tumours, Clinical Endocrinology, 59, 793, 10.1046/j.1365-2265.2003.01931.x de Herder, 2005, Neuroendocrine tumors and somatostatin: imaging techniques, Journal of Endocrinological Investigation, 28, 132 Lanberts, 1990, Parellel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regards to diagnosis, localization and therapy, The Journal of Clinical Endocrinology and Metabolism, 71, 566, 10.1210/jcem-71-3-566 Janson, 1994, 111In-DTPA-D-Phe1 Octreotide scintigraphy in patients with carcinoid tumors: the predictive value for somatostatin analogue treatment, European Journal of Endocrinology, 131, 577, 10.1530/eje.0.1310577 Reubi, 2005, Candidates for peptide receptor radiotherapy today and in the future, Journal of Nuclear Medicine, 46, 67S Kaltsas, 2001, Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors, The Journal of Clinical Endocrinology and Metabolism, 86, 895, 10.1210/jc.86.2.895 Ezziddin, 2006, Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors, Journal of Nuclear Medicine, 47, 223 Mukherjee, 2001, Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG], Clinical Endocrinology, 55, 47, 10.1046/j.1365-2265.2001.01309.x Buscombe, 2005, Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response, Nuclear Medicine Communications, 26, 969, 10.1097/01.mnm.0000184941.06123.b9 Brogsitter, 2005, Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG, Journal of Nuclear Medicine, 46, 2112 Rufini, 2006, Imaging of neuroendocrine tumors, Seminars in Nuclear Medicine, 36, 228, 10.1053/j.semnuclmed.2006.03.007 Lin, 2005, Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma, Nuclear Medicine Communications, 26, 315, 10.1097/00006231-200504000-00003 von Schulthess, 2006, Integrated PET/CT: current applications and future directions, Radiology, 238, 405, 10.1148/radiol.2382041977 Ell, 2006, The contribution of PET/CT to improved patient management, The British Journal of Radiology, 79, 32, 10.1259/bjr/18454286 Reske, 2001, FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, ‘Onko-PET III’, 21 July and 19 September 2000', European Journal of Nuclear Medicine, 28, 1707, 10.1007/s002590100626 Kapoor, 2004, An introduction to PET-CT imaging, Radiographics, 24, 523, 10.1148/rg.242025724 Gambhir, 2001, A tabulated summary of the FDG PET literature, Journal of Nuclear Medicine, 42, 1S Bunyaviroch, 2006, PET evaluation of lung cancer, Journal of Nuclear Medicine, 47, 451 Kim, 2006, Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT-A prospective study, Radiology, 241, 501, 10.1148/radiol.2412051173 Chin, 2003, 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies, Gut, 52, 23, 10.1136/gut.52.suppl_4.iv23 Kantorova, 2003, Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making, Journal of Nuclear Medicine, 44, 1784 Esteves, 2006, Gastrointestinal tract malignancies and positron emission tomography: an overview, Seminars in Nuclear Medicine, 36, 169, 10.1053/j.semnuclmed.2005.12.002 Rodriguez, 1997, [18F] FDG PET in gastric non-Hodgkin's lymphoma, Acta Oncologica (Stockholm, Sweden), 36, 577, 10.3109/02841869709001319 Juweid, 2005, Role of positron emission tomography in lymphoma, Journal of Clinical Oncology, 23, 4577, 10.1200/JCO.2005.01.904 Kapoor, 2005, Role of [18F]FDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging, American Journal of Roentgenology, 184, 579, 10.2214/ajr.184.2.01840579 Belhocine, 2006, Role of nuclear medicine in the management of cutaneous malignant melanoma, Journal of Nuclear Medicine, 47, 957 Bastiaannet, 2006, Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients, The British Journal of Surgery, 93, 243, 10.1002/bjs.5174 Kumar, 2006, Positron emission tomography in gynecological malignancies, Expert Review of Anticancer Therapy, 6, 1033, 10.1586/14737140.6.7.1033 Jarritt, 2006, The role of PET/CT scanning in radiotherapy planning, The British Journal of Radiology, 79, S27, 10.1259/bjr/35628509 Adams, 1998, Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors, European Journal of Nuclear Medicine, 25, 79, 10.1007/s002590050197 Pasquali, 1998, Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?, World Journal of Surgery, 22, 588, 10.1007/s002689900439 Foidart-Willems, 1995, Positron emission tomography and radio labeled octreotide scintigraphy in carcinoid tumors, European Journal of Nuclear Medicine, 22, 635 Jadavar, 1997, False-negative fluorine-18-FDG-PET in metastatic carcinoid, Journal of Nuclear Medicine, 38, 1382 Pacak, 2004, The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome, The Journal of Clinical Endocrinology and Metabolism, 89, 2214, 10.1210/jc.2003-031812 Kumar, 2006, 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours, Clinical Endocrinology, 64, 371 Pearse, 1980, The APUD concept and hormone production, Clinics in Endocrinology and Metabolism, 9, 211, 10.1016/S0300-595X(80)80030-2 Ahlström, 1995, Pancreatic neuroendocrine tumours: Diagnosis with PET, Radiology, 195, 333, 10.1148/radiology.195.2.7724749 Hoegerle, 2001, Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors, Radiology, 220, 373, 10.1148/radiology.220.2.r01au25373 Becherer, 2004, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET, Journal of Nuclear Medicine, 45, 1161 Koopmans, 2006, Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study, The Lancet Oncology, 7, 728, 10.1016/S1470-2045(06)70801-4 Montravers, 2006, Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?, Journal of Nuclear Medicine, 47, 1455 Hoegerle, 2001, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels, European Journal of Nuclear Medicine, 28, 64, 10.1007/s002590000404 Hoegerle, 2002, Pheochromocytomas: detection with 18F DOPA whole body PET-initial results, Radiology, 222, 507, 10.1148/radiol.2222010622 Nanni, 2006, 18F-DOPA PET/CT and neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, 33, 509, 10.1007/s00259-006-0079-5 Örlefors, 1998, Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors, Journal of Clinical Oncology, 16, 2534, 10.1200/JCO.1998.16.7.2534 Örlefors, 2006, Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography, European Journal of Nuclear Medicine and Molecular Imaging, 33, 60, 10.1007/s00259-005-1891-z Brown, 1998, Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment, Journal of Nuclear Medicine, 39, 1884 Örlefors, 2005, Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography, The Journal of Clinical Endocrinology and Metabolism, 90, 3392, 10.1210/jc.2004-1938 Hofmann, 2001, Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data, European Journal of Nuclear Medicine, 28, 1751, 10.1007/s002590100639 Kowalski, 2003, Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors, Molecular Imaging and Biology, 5, 42, 10.1016/S1536-1632(03)00038-6 Koukouraki, 2006, Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy, European Journal of Nuclear Medicine and Molecular Imaging, 33, 460, 10.1007/s00259-005-0006-1 Win, 2006, The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, 33, 506, 10.1007/s00259-005-0035-9